English | 简体中文 | LP ACCESS

About artrix

This author has not yet filled in any details.
So far artrix has created 73 blog entries.

Ablaze Pharmaceuticals Launches with $75M Series A Financing to Bring Novel Targeted Radiopharmaceuticals to Treat Cancer Patients in the Greater China Market 

Ablaze Pharmaceuticals Launches with $75M Series A Financing to Bring Novel Targeted Radiopharmaceuticals to Treat Cancer Patients in the Greater China Market 2022-03-09T21:58:39-08:00

Aadi Bioscience Announces FDA Approval FYARRO™ for Patients with Locally Advanced Unresectable or Metastatic Malignant Perivascular Epithelioid Cell Tumor (PEComa)

Aadi Bioscience Announces FDA Approval FYARRO™ for Patients with Locally Advanced Unresectable or Metastatic Malignant Perivascular Epithelioid Cell Tumor (PEComa)2022-03-09T21:51:12-08:00

Ascendis Pharma A/S Announces U.S. FDA Approval of SKYTROFA®, the First Once-weekly Treatment for Pediatric Growth Hormone Deficiency

Ascendis Pharma A/S Announces U.S. FDA Approval of SKYTROFA®, the First Once-weekly Treatment for Pediatric Growth Hormone Deficiency2022-03-09T20:15:49-08:00

PALO ALTO
GLOBAL HEADQUARTERS

BEIJING
 

SHANGHAI  
 

TAIPEI   
 

HONG KONG    
 

ESG | Privacy Policy | Email: info@vivocapital.com
Vivo Capital®, SEC registered, effective 6/19/2014. All rights reserved.
Go to Top